GlassScriptPhysician profile
Ankur Sarkar
NPI 1205869633
$4,834.08
in general payments reported to CMS, 2019-2025
31 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $503 · 2021: $809 · 2022: $752 · 2023: $1,104 · 2024: $1,110 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,750 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.70 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $670.99 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $601.02 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $425.53 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.02 | 2022-2025 | Jardiance, Trijardy Xr, Synjardy |
| Abbvie INC. | $366.75 | 2021-2025 | Vraylar |
| Amgen INC. | $271.38 | 2020-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $253.54 | 2020-2023 | Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $211.94 | 2024-2025 | |
| Medtronic, INC. | $211.41 | 2021-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $206.15 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.60 | 2020-2025 | Xifaxan |
| Allergan, INC. | $142.45 | 2020 | |
| Genzyme Corporation | $141.40 | 2024 | |
| Novartis Pharmaceuticals Corporation | $126.79 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.93 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.67 | 2020-2025 | |
| Angiodynamics, INC. | $92.55 | 2021 | |
| Impulse Dynamics (USA) INC. | $63.60 | 2022-2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $60.73 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $38.89 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $32.52 | 2020 | |
| Globus Medical, INC. | $28.08 | 2025 | Senza |
| Paratek Pharmaceuticals, INC. | $20.48 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.36 | 2021 | |
| Currax Pharmaceuticals LLC | $16.47 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $16.31 | 2021 | |
| Shield Therapeutics INC | $16.24 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $15.96 | 2022 | |
| Exact Sciences Corporation | $14.23 | 2023 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $13.56 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amneal Pharmaceuticals LLC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Sarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.